Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial-MedSci.cn

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial

Li, DD; Tao, ZH; Wang, BY; Wang, LP; Cao, J; Hu, XC; Zhang, J

Hu, XC; Zhang, J (通讯作者)，Fudan Univ, Dept Med Oncol, Shanghai, Peoples R China.;Hu, XC; Zhang, J (通讯作者)，Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China.;Hu, XC; Zhang, J (通讯作者)，Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China.

Abstract

While therapies such as chemotherapy combined with immunotherapy, sacituzumab govitecan, and PARP inhibitors are available for metastatic TNBC, on dis......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial

科室

工具

服务